Search Results
Sep 04, 2026, 06:33 ET GPGI INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against GPGI, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead Class Action Lawsuit Before September 14, 2026 Deadline
track to achieve the revenue and Adjusted EBITDA targets provided in the proxy statement and such targets lacked a reasonable basis in objective fact; (iii) a primary motivation of the Husky Acquisition was to generate millions of dollars in fees for Resolute Holdings and the individual defendants, rather
More news about: Robbins Geller Rudman & Dowd LLP
Sep 04, 2026, 01:54 ET 화웨이, 뮌헨 '야성을 좇다' 글로벌 혁신 제품 출시 행사에서 차세대 플래그십 제품 공개
참고용으로만 제공되며 의료 진단이나 치료의 근거로 사용해서는 안 된다.[iii] 이 기능은 의료 목적으로 사용할 수 없다. 결과는 참고용으로만 제공되며 의료 진단이나 치료의 근거로 사용해서는 안 된다.
More news about: Huawei
Sep 04, 2026, 01:49 ET Huawei Perkenalkan Produk Flagship Generasi Baru dalam Acara Peluncuran Produk Global "Chase the Wild" di Munich
pengukuran hanya menjadi referensi, bukan sebagai dasar diagnosis atau pengobatan medis.[iii] Fitur ini bukan untuk keperluan medis. Hasil pengukuran hanya menjadi referensi, bukan sebagai dasar diagnosis atau pengobatan medis.
More news about: Huawei
Sep 04, 2026, 00:25 ET Huawei presenta sus productos estrella de última generación en el evento mundial de lanzamiento "Chase the Wild", celebrado en Múnich
médico ni para un tratamiento.[iii] Esta función no está destinada a uso médico. Los resultados son meramente orientativos y no deben utilizarse como base para un diagnóstico médico
More news about: Huawei
Sep 03, 2026, 19:10 ET REGN INVESTOR ALERT: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit
and/or failed to disclose that: (i) defendants created the false impression that they possessed reliable information demonstrating that Regeneron's Phase III Fianlimab-Libtayo Study was well-poised for success, while minimizing risks to the study's odds of achieving its primary endpoint and its overall statistical
More news about: Robbins Geller Rudman & Dowd LLP
Sep 03, 2026, 19:00 ET KANEKA UBIQUINOL™ WINS NUTRAINGREDIENTS ASIA INGREDIENT OF THE YEAR: HEALTHSPAN AWARD 2026
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00098-8/fulltext[iii] San-Millán I. Antioxidants (Basel) 2023;12(4):782.
More news about: Kaneka Ubiquinol™
Sep 03, 2026, 19:00 ET KANEKA UBIQUINOL™ WINS NUTRAINGREDIENTS ASIA INGREDIENT OF THE YEAR: HEALTHSPAN AWARD 2026
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2667(26)00098-8/fulltext[iii] San-Millán I. Antioxidants (Basel) 2023;12(4):782.
More news about: Kaneka Ubiquinol™
Sep 03, 2026, 17:30 ET Palm Beach Illustrated Names 21 Greenberg Traurig West Palm Beach Attorneys to 2026 'Top Lawyers' List
Joseph C. Coates III: Administrative/Regulatory Law; Securities Regulation
More news about: Greenberg Traurig, LLP
Sep 03, 2026, 17:00 ET Prologis to Announce Third Quarter 2026 Results October 15, 2026
local economic and political climates and conditions; (ii) changes in global financial markets, interest rates and foreign currency exchange rates; (iii) increased or unanticipated competition for our properties; (iv) risks associated with acquisitions, dispositions and development of properties, including
More news about: Prologis, Inc.
Sep 03, 2026, 16:05 ET American Outdoor Brands, Inc. Reports First Quarter Fiscal 2027 Financial Results
and the reader to review, as applicable, both (1) GAAP measures that include (i) amortization of acquired intangible assets, (ii) stock compensation, (iii) contract exit costs, (iv) income tax adjustments, (v) interest income, (vi) income tax expense, and (vii) depreciation and amortization; and (2) the
More news about: American Outdoor Brands, Inc.
Sep 03, 2026, 15:32 ET Faruqi & Faruqi, LLP Urges Microvast Holdings, Inc. (NASDAQ: MVST) Investors to Seek Counsel Before September 21, 2026 Lead Plaintiff Deadline in the Securities Class Action
ability to reach its margin targets; (ii) Defendants overstated Microvast's ability to complete the Huzhou Phase 3.2 expansion by the end of 2025; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.Faruqi & Faruqi, LLP also encourages
More news about: Faruqi & Faruqi, LLP
Sep 03, 2026, 15:08 ET Hyperscale Data's Net Book Value Was Approximately $0.95 Per Share and Its Gross Asset Value Was Approximately $3.10 Per Share as of June 30, 2026
does not reflect the Company's liabilities and therefore should not be interpreted as net book value or liquidation value.Milton "Todd" Ault III, Executive Chairman of Hyperscale Data, stated, "We believe it is important for stockholders to understand the balance sheet underlying Hyperscale Data.
More news about: Hyperscale Data Inc.
Sep 03, 2026, 13:54 ET Huawei ra mắt loạt sản phẩm chủ lực thế hệ tiếp theo tại sự kiện ra mắt sản phẩm đổi mới sáng tạo toàn cầu "Chase the Wild" tại Munich
mang tính tham khảo và không nên được sử dụng làm cơ sở để chẩn đoán hoặc điều trị y tế.[iii] Tính năng này không dành cho mục đích y tế. Kết quả chỉ mang tính tham khảo và không nên được sử dụng làm cơ sở để chẩn đoán hoặc điều trị y tế.
More news about: Huawei
Sep 03, 2026, 13:31 ET Datavault AI, Inc. (DVLT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Plaintiff and other Class members, as alleged herein; (ii) artificially inflate and maintain the market price of Datavault AI securities; and (iii) cause Plaintiff and other members of the Class to purchase or otherwise acquire Datavault AI securities and options at artificially inflated prices.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Sep 03, 2026, 13:25 ET Huawei revelou seus produtos emblemáticos de última geração durante o evento global de lançamento "Chase the Wild", realizado em Munique
diagnóstico ou tratamento médico.[iii] Essa funcionalidade não se destina ao uso médico. Os resultados são apenas para referência e não devem ser usados como base para diagnóstico ou tratamento
More news about: Huawei
Sep 03, 2026, 13:14 ET Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Revita's clinical, regulatory, and commercial prospects were overstated, as was the REMAIN-1 Midpoint Cohort's ability to assess Revita's efficacy; and (iii) as a result, Defendants' public statements were materially false and misleading at all relevant times.Contact Us To Participate or Learn More:If
More news about: Law Offices of Howard G. Smith
Sep 03, 2026, 13:08 ET Gan & Lee a Menarini Group uzavřely partnerství k prosazení přípravku bofanglutid v Evropě
podkožní podávání jednou za dva týdny, což snižuje frekvenci podávání o 50 % ve srovnání s léky GLP-1 RA podávanými jednou týdně. Klíčová studie fáze III v Číně a studie fáze II ve Spojených státech zaměřené na regulaci hmotnosti u dospělých s obezitou nebo nadváhou splnily své primární cíle, čímž prokázaly
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 13:01 ET Gan & Lee et le groupe Menarini s'associent pour faire progresser le bofanglutide en Europe
semaines, ce qui réduit la fréquence d'administration de 50 % par rapport aux agonistes du GLP-1 à administration hebdomadaire . L'étude pivot de phase III menée en Chine et l'étude de phase II menée aux États-Unis sur la gestion du poids chez les adultes souffrant d'obésité ou de surpoids ont toutes deux
More news about: Menarini Industrie Farmaceutiche Riunite
Sep 03, 2026, 12:33 ET Huawei presenta i prodotti di nuova generazione all'evento globale di lancio "Chase the Wild" a Monaco di Baviera
diagnosi o trattamenti medici.[Iii] La funzione non è destinata a uso medico. I risultati sono solo di riferimento e non devono essere utilizzati come base per diagnosi o trattamenti
More news about: Huawei
Sep 03, 2026, 12:26 ET Huawei onthult vlaggenschipproducten van de volgende generatie tijdens wereldwijd innovatief productlanceringsevenement "Chase the Wild" in München
behandeling worden gebruikt.[iii] De functie is niet bedoeld voor medisch gebruik. De resultaten dienen uitsluitend als referentie en mogen niet als basis voor een medische diagnose
More news about: Huawei
Sep 03, 2026, 12:00 ET Aevex Corp. (AVEX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
significant portion of its Aevex holdings in the SPO, and the entirety of the SPO's net proceeds went to Madison, with Aevex earning zero from the SPO; (iii) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable
More news about: Law Offices of Howard G. Smith
Sep 03, 2026, 11:56 ET California Baptist University expands career preparation, announces Modern Woodmen sponsorship
opportunities in 2018."CBU has been an integral part of our recruiting efforts since we first came to campus in 2018," said Bennett L. Sperber III, managing director at Modern Woodmen Fraternal Financial. "We see strong alignment between CBU's values and our own, but we also see students who are
More news about: California Baptist University
Sep 03, 2026, 11:00 ET Havoc and Rune Technologies Announce Integration to Deliver Autonomous Logistics at the Edge
the field. On August 16, 2026, Rune Technologies successfully integrated TyrOS with Havoc's autonomous drones during xTech Overwatch's Pegasus Charge III exercise at Fort Hood, Texas, where the two companies completed an end-to-end autonomous resupply mission for the first time, in a live operational setting.About
More news about: Havoc AI
Sep 03, 2026, 10:41 ET Huawei prezentuje flagowe produkty nowej generacji podczas światowej premiery „Chase the Wild" w Monachium
podstawy diagnozy ani leczenia.[iii] Funkcja nie jest przeznaczona do zastosowań medycznych. Wyniki mają charakter wyłącznie orientacyjny i nie powinny stanowić podstawy diagnozy
More news about: Huawei
Sep 03, 2026, 10:07 ET REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt
Market impact notice: REGN shares allegedly lost $102.09 from the Class Period high after disclosures about a Phase III Fianlimab-Libtayo protocol change and failed primary endpoint challenged earlier positive trial-risk messaging.NEW YORK,
More news about: SueWallSt.com